中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(5): 1059-1063

Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C

DOI: 10.3969/j.issn.1001-5256.2022.05.016

  • Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

Research funding:

National Science and Technology Major Project (2017ZX10302201-004-009);

National Science and Technology Major Project (2017ZX10203202-003);

National Science and Technology Major Project (2018ZX09201016);

Beijing Science and Technology Plan Project (D171100003117005);

Beijing Science and Technology Plan Project (D161100002716002);

Beijing Science and Technology Plan Project (D161100002716003)

More Information
  • Corresponding author: XU Xiaoyuan, xiaoyuanxu6@163.com (ORCID: 0000-0002-1759-4330)
  • Received Date: 2022-01-24
  • Accepted Date: 2022-04-12
  • Published Date: 2022-05-20
    Abstract
  •   Objective  To investigate the influencing factors for direct-acting antiviral agent (DAA) therapy failure in the treatment of hepatitis C by comparing baseline clinical data and resistance-associated substitution (RAS) in sequencing data between the patients with HCV RNA reactivation after DAA therapy and the patients with successful DAA treatment.  Methods  A total of 13 patients from multiple centers who failed DAA therapy from November 2019 to October 2021 were enrolled as treatment failure group, and sequencing was performed for their positive serum samples. A total of 51 patients with successful DAA treatment were enrolled as control group, and baseline clinical data and sequencing results were compared between the treatment failure group and the control group. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups, and the chi-square test was used for comparison of categorical data between groups; univariate and multivariate logistic regression analyses were performed to calculate odds ratio (OR) and investigate the influencing factors for treatment failure.  Results  All 12 patients with complete treatment data experienced recurrence within 1 year after the end of medication. The male patients with treatment failure had significantly higher baseline total bilirubin, direct bilirubin, and creatinine than their female counterparts (Z=-2.517, -2.440, and -2.132, P=0.010, 0.010, and 0.038), and the patients with an age of ≤55 years (OR=5.152, 95% confidence interval [CI]: 1.116-23.790, P=0.036) or genotype 3b (OR=9.726, 95%CI: 1.325-71.398, P=0.025) had a higher probability of treatment failure. There were differences in the incidence rates of major RAS mutations on three gene fragments between the treatment failure group and the treatment success group, and the common RAS mutations detected in the treatment failure group were not detected in the treatment success group.  Conclusion  Age, genotype, and RAS in serum virus gene sequence are influencing factors for DAA treatment failure.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [2]
    CHEN HY, KANG Q, LUO H, et al. Virological response to direct-acting antiviral therapy and changes in liver fibrosis indices in chronic hepatitis C patients with different alanine aminotransferase and aspartate aminotransferase levels in a real-world setting[J]. J Clin Hepatol, 2021, 37(2): 314-317. DOI: 10.3969/j.issn.1001-5256.2021.02.014.

    陈宏宇, 亢倩, 罗皓, 等. 真实世界中不同ALT、AST水平慢性丙型肝炎患者对直接抗病毒药物治疗的病毒学应答及肝纤维化指标变化情况[J]. 临床肝胆病杂志, 2021, 37(2): 314-317. DOI: 10.3969/j.issn.1001-5256.2021.02.014.
    [3]
    LOHMANN V, KÖRNER F, KOCH J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science, 1999, 285(5424): 110-113. DOI: 10.1126/science.285.5424.110.
    [4]
    CHEN JH, XU XY. Research of HCV variants resistant to direct-acting antiviral agents[J]. Infect Dis Info, 2016, 29(2): 116-120. DOI: 10.3969/j.issn.1007-8134.2016.02.014.

    陈建宏, 徐小元. 丙型肝炎直接抗病毒药物耐药相关变异的研究[J]. 传染病信息, 2016, 29(2): 116-120. DOI: 10.3969/j.issn.1007-8134.2016.02.014.
    [5]
    PAWLOTSKY JM. Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures[J]. Semin Liver Dis, 2019, 39(3): 354-368. DOI: 10.1055/s-0039-1687823.
    [6]
    WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(2): 127-134. DOI: 10.1016/S2468-1253(18)30343-1.
    [7]
    DIETZ J, SUSSER S, VERMEHREN J, et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals[J]. Gastroenterology, 2018, 154(4): 976-988. e4. DOI: 10.1053/j.gastro.2017.11.007.
    [8]
    BAUMERT TF, BERG T, LIM JK, et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges[J]. Gastroenterology, 2019, 156(2): 431-445. DOI: 10.1053/j.gastro.2018.10.024.
    [9]
    KOMATSU TE, BOYD S, SHERWAT A, et al. Regulatory analysis of effects of hepatitis C Virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir[J]. Gastroenterology, 2017, 152(3): 586-597. DOI: 10.1053/j.gastro.2016.10.017.
    [10]
    DONALDSON EF, HARRINGTON PR, O'REAR JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir[J]. Hepatology, 2015, 61(1): 56-65. DOI: 10.1002/hep.27375.
    [11]
    FELD JJ, JACOBSON IM, HÉZODE C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection[J]. N Engl J Med, 2015, 373(27): 2599-2607. DOI: 10.1056/NEJMoa1512610.
    [12]
    SORBO MC, CENTO V, DI MAIO VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018[J]. Drug Resist Updat, 2018, 37: 17-39. DOI: 10.1016/j.drup.2018.01.004.
    [13]
    ZHOU N, HERNANDEZ D, UELAND J, et al. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection[J]. J Infect Dis, 2016, 213(2): 206-215. DOI: 10.1093/infdis/jiv379.
    [14]
    LAWITZ EJ, DVORY-SOBOL H, DOEHLE BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein[J]. Antimicrob Agents Chemother, 2016, 60(9): 5368-5378. DOI: 10.1128/AAC.00763-16.
    [15]
    LIU R, CURRY S, MCMONAGLE P, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir[J]. Antimicrob Agents Chemother, 2015, 59(11): 6922-6929. DOI: 10.1128/AAC.01390-15.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (468) PDF downloads(56) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return